Lip, Gregory Y. H.
Fauchier, Laurent
Freedman, Saul B.
Van Gelder, Isabelle
Natale, Andrea
Gianni, Carola
Nattel, Stanley
Potpara, Tatjana
Rienstra, Michiel
Tse, Hung-Fat
Lane, Deirdre A.
Article History
First Online: 31 March 2016
Competing interests
: G.Y.H.L. has had guideline membership or has been involved in reviewing the European Society of Cardiology (ESC) Guidelines on Atrial Fibrillation (2010) and Focused Update (2012), the ESC Guidelines on Heart Failure (2012), the American College of Chest Physicians Antithrombotic Therapy Guidelines for Atrial Fibrillation (2012), the National Institute for Health and Care Excellence (NICE) Guidelines on Atrial Fibrillation (2006 and 2014), the NICE Quality Standards on Atrial Fibrillation (2015), the ESC Cardio-oncology Task Force (2015) and the ESC Working Group on Thrombosis position documents (2011–present). He is the chairman of the Scientific Documents Committee for the European Heart Rhythm Association (EHRA) and a reviewer for various guidelines and position statements from the ESC, EHRA, NICE and other organizations. He has been a member of steering committees for various Phase II and III studies, Health Economics and Outcomes Research and other studies, and has been an investigator in various clinical trials in cardiovascular disease, including those on antithrombotic therapies in atrial fibrillation, acute coronary syndrome and lipids. He has been or is currently a consultant for Bayer/Janssen, Astellas, Merck, Sanofi, BMS/Pfizer, Biotronik, Medtronic, Portola, Boehringer Ingelheim, Microlife and Daiichi-Sankyo, and a speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-Sankyo. L.F. has served as a consultant for Bayer HealthCare, Bristol-Myers Squibb/Pfizer, Boehringer Ingelheim, Medtronic and Novartis and has been on the speakers' bureau for Bayer HealthCare, Bristol-Myers Squibb/Pfizer, Boehringher Ingelheim, Boston Scientific and Medtronic. S.B.F. receives investigator-initiated research grants, personal fees and non-financial support from Bayer Pharma AG, investigator-initiated research grants and non-financial support from Boehringer Ingelheim, investigator-initiated research grants and personal fees from Bristol-Myers Squibb/Pfizer and personal fees from Servier, AstraZeneca and Gilead Sciences. These associations are not related to the submitted work. I.V.G. has had guideline membership of and been involved in reviewing the ESC Guidelines on Atrial Fibrillation (2010). She has received research grants that have been paid to the University Medical Center Groningen from Medtronic, Biotronik and St Jude Medical. A.N. has received consulting fees or honoraria from Janssen Pharmaceuticals, Biosense Webster, St Jude Medical, Medtronic and Boston Scientific. C.G. declares no competing interests. S.N. declares no competing interests. T.P. has received consultant and speaker fees from Bayer HealthCare, Pfizer and Boehringer Ingelheim. M.R. is supported by a grant from the Netherlands Organization for Scientific Research (Veni grant number 016.136.055). He declares no relationship with industry. H.-F.T. is chairman of the Clinical Trial Committee for the Asia Pacific Heart Rhythm Society. He has been or is currently a steering committee member and investigator in various clinical trials in cardiovascular disease, including those on antithrombotic therapies in atrial fibrillation, acute coronary syndrome and lipids. He has been or is currently a consultant for BayerHealthcare/Jensen J&J, MSD, Bristol-Myers Squibb/Pfizer, Boston Scientific, St Jude Medical, Medtronic, Boehringer Ingelheim and Daiichi-Sankyo, and a speaker for Bayer HealthCare/Jensen J&J, MSD, Bristol-Myers Squibb/Pfizer, Boston Scientific, St Jude Medical, Medtronic, Boehringer Ingelheim and Merck. D.A.L. has received investigator-initiated educational grants from Bayer HealthCare, Bristol-Myers Squibb and Boehringer Ingelheim and has been on the speaker bureau for Boehringer Ingelheim, Bayer HealthCare and Bristol-Myers Squibb/Pfizer. She is a steering committee member of a Bristol-Myers Squibb Phase IV trial.